Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA.
Novant Health Cancer Institute, Charlotte, NC, USA.
Curr Treat Options Oncol. 2024 Apr;25(4):496-509. doi: 10.1007/s11864-024-01189-1. Epub 2024 Feb 19.
This paper shines a light on the exciting progress being made in using immunotherapy to treat advanced gastroesophageal cancers. The positive results from trials using drugs like Pembrolizumab and Nivolumab are certainly encouraging and open new possibilities for treating this challenging disease. However, it is clear that we still have a lot to learn about how to predict which patients will benefit most from these treatments. The exploration of combining therapies and using machine learning to guide treatment shows promise. Moving forward, it is crucial that researchers and healthcare professionals continue to work together, sharing knowledge and findings to continue the advancements in this important area.
本文探讨了免疫疗法在治疗晚期胃食管癌症方面取得的令人振奋的进展。使用 Pembrolizumab 和 Nivolumab 等药物的试验结果确实令人鼓舞，为治疗这种具有挑战性的疾病开辟了新的可能性。然而，很明显，我们仍然需要了解更多关于如何预测哪些患者将从这些治疗中获益最大的知识。探索联合治疗和使用机器学习来指导治疗显示出了希望。展望未来，研究人员和医疗保健专业人员继续合作，分享知识和发现，以继续推动这一重要领域的进展至关重要。
